IA
KRYS icon

IndexIQ Advisors’s Krystal Biotech KRYS Stock Holding History

IndexIQ Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,844
Closed -$291K – 1230
2020
Q4 		$291K Buy
4,844
+500
+12% +$25K 0.01% 693
2020
Q3 		$187K Buy
4,344
+235
+6% +$10.2K 0.01% 697
2020
Q2 		$170K Sell
4,109
-580
-12% -$27.9K 0.01% 737
2020
Q1 		$203K Buy
+4,689
New +$245K 0.01% 293

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

IndexIQ Advisors's KRYS Position: Q1 2021 in Review

IndexIQ Advisors sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 4,844 shares — an estimated $291K sold.

IndexIQ Advisors first reported a position in KRYS in Q1 2020 and held it in 4 quarters. The position peaked at $291K in Q4 2020. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

  • IndexIQ Advisors reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
  • IndexIQ Advisors sold 4,844 Krystal Biotech shares in Q1 2021, an estimated $291K.
  • IndexIQ Advisors first reported a position in Krystal Biotech in Q1 2020 and held it in 4 quarters.
  • IndexIQ Advisors's Krystal Biotech position peaked at $291K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on IndexIQ Advisors's 13F filing for Q1 2021, filed 7 May 2021.